Literature DB >> 19061880

Inhibition of the activity of Rho-kinase reduces cardiomyocyte apoptosis in heart ischemia/reperfusion via suppressing JNK-mediated AIF translocation.

Juan Zhang1, Xiao-Xing Li, Hong-Jun Bian, Xiao-Bo Liu, Xiao-Ping Ji, Yun Zhang.   

Abstract

BACKGROUND: Recent studies have demonstrated that Rho-kinase has been proposed to play an important role in the pathogenesis of heart ischemia/reperfusion (I/R) injury. However, the mechanism of Rho-kinase mediated cardiomyocyte apoptosis in I/R is still not thoroughly understood.
METHOD: Studies were performed with female Wistar rats.
RESULTS: Ischemia followed by reperfusion caused a significant increase in Rho-kinase, c-Jun NH2-terminal kinase (JNK) and apoptosis-inducing factor (AIF) activity. Administration of fasudil, an inhibitor of Rho-kinase, decreased myocardial infarction size from 59.89+/-3.83% to 38.62+/-2.66% (P<0.05) and cell apoptosis from 32.78+/-5.1% to 17.05+/-4.2% (P<0.05). Western blot analysis showed that administration of fasudil reduced the activation of JNK and attenuated mitochondrial-nuclear translocation of AIF. Additionally, administration of SP600125, an inhibitor of JNK, attenuated mitochondrial-nuclear translocation of AIF.
CONCLUSION: The inhibition of Rho-kinase reduced cell apoptosis in I/R in vivo via suppression of JNK-mediated AIF translocation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19061880     DOI: 10.1016/j.cca.2008.11.016

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  21 in total

Review 1.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

Review 2.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

3.  ERK-MAPK signaling opposes rho-kinase to reduce cardiomyocyte apoptosis in heart ischemic preconditioning.

Authors:  Juan Zhang; Hong-Jun Bian; Xiao-Xing Li; Xiao-Bo Liu; Jun-Ping Sun; Na Li; Yun Zhang; Xiao-Ping Ji
Journal:  Mol Med       Date:  2010-03-17       Impact factor: 6.354

Review 4.  Rho kinase as a therapeutic target in cardiovascular disease.

Authors:  Michelle Surma; Lei Wei; Jianjian Shi
Journal:  Future Cardiol       Date:  2011-09

Review 5.  Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives.

Authors:  Sabzali Javadov; Sehwan Jang; Bryan Agostini
Journal:  Pharmacol Ther       Date:  2014-06-09       Impact factor: 12.310

6.  The ubiquitin ligase MuRF1 protects against cardiac ischemia/reperfusion injury by its proteasome-dependent degradation of phospho-c-Jun.

Authors:  Hui-Hua Li; Jie Du; Yong-Na Fan; Mei-Li Zhang; De-Pei Liu; Luge Li; Pamela Lockyer; Eunice Y Kang; Cam Patterson; Monte S Willis
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

7.  Rho-kinase inhibition is involved in the activation of PI3-kinase/Akt during ischemic-preconditioning-induced cardiomyocyte apoptosis.

Authors:  Juan Zhang; Xiao-Bo Liu; Chao Cheng; Dong-Ling Xu; Qing-Hua Lu; Xiao-Ping Ji
Journal:  Int J Clin Exp Med       Date:  2014-11-15

8.  Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype.

Authors:  Sree Rayavarapu; Jack H Van der Meulen; Heather Gordish-Dressman; Eric P Hoffman; Kanneboyina Nagaraju; Susan M Knoblach
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

9.  The Effects of Fasudil at Different Doses on Acute Myocardial Infarction in Rats.

Authors:  Lijuan Tan; Nana Pan; Lingfan Yu; Renchao Yu; Bin Yang
Journal:  Acta Cardiol Sin       Date:  2013-11       Impact factor: 2.672

10.  MicroRNA-145-5p inhibits hypoxia/reoxygenation-induced apoptosis in H9c2 cardiomyocytes by targeting ROCK1.

Authors:  Chao Cheng; Dong-Ling Xu; Xiao-Bo Liu; Shao-Jie Bi; Juan Zhang
Journal:  Exp Ther Med       Date:  2021-05-25       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.